Scarica l'app Stockscreener
46.24
2.19%
0.99
Dopo l'orario di chiusura:
46.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$45.25
Aprire:
$44.77
Volume 24 ore:
1.22M
Relative Volume:
1.52
Capitalizzazione di mercato:
$3.57B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-5.3457
EPS:
-8.65
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-0.28%
1M Prestazione:
+10.20%
6M Prestazione:
+38.90%
1 anno Prestazione:
+71.01%
Intervallo 1D:
$44.74
$47.42
Intervallo di 1 settimana:
$44.30
$48.77
Portata 52W:
$23.58
$54.16
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
46.24 | 3.57B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
PTC upgraded to outperform by RBC on Novartis deal - MSN
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down - MSN
PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone - MSN
PTC Therapeutics Submits Vantiquinone NDA To FDA - Contract Pharma
PTC Therapeutics submits FDA application for FA treatment - Investing.com
PTC Therapeutics Seeks FDA Approval for Groundbreaking Friedreich Ataxia Treatment in Children - StockTitan
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
PTC Therapeutics Submits Vantiquinone NDA to FDA - Contract Pharma
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to "Hold" at StockNews.com - MarketBeat
PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia - Marketscreener.com
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN
PTC Therapeutics Grants New Employee Stock Options and RSUs in Strategic Talent Acquisition Move - StockTitan
PTC Therapeutics' SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Y Intercept Hong Kong Ltd Sells 18,312 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
State Street Corp Purchases 149,700 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Morgan Stanley Upgrades PTC Therapeutics (PTCT) - MSN
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
PTC Therapeutics upgraded to Overweight at Morgan Stanley - MSN
PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Overweight at Morgan Stanley - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast - BioCentury
Two Sigma Advisers LP Grows Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Fmr LLC Trims Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Wellington Management Group LLP Sells 315,807 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
BNP Paribas Financial Markets Sells 54,655 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
At $1B, PTC-Novartis deal ties record for cash up front - BioCentury
Janus Henderson Group PLC Sells 1,111,342 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Global Leigh Syndrome Treatment Market Outlook: Key Trends, - openPR
PTC Therapeutics (STU:BH3) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
PTC Therapeutics (STU:BH3) 9-Day RSI : 64.15 (As of Dec. 05, 2024) - GuruFocus.com
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy - MSN
Ptc Therapeutics exec VP sells shares worth $5 million By Investing.com - Investing.com Canada
PTC Therapeutics director Jerome Zeldis sells $1.24m in stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics price target raised to $41 from $31 at BofA - MSN
Ptc Therapeutics' chief accounting officer sells shares worth $921,585 By Investing.com - Investing.com Canada
Insider Sell Alert: Christine Utter Sells 17,800 Shares of PTC T - GuruFocus.com
Insider Sell Alert: Jerome Zeldis Sells 24,000 Shares of PTC The - GuruFocus.com
Ptc Therapeutics exec VP sells shares worth $5 million - Investing.com
Ptc Therapeutics' chief accounting officer sells shares worth $921,585 - Investing.com
PTC Therapeutics director Jerome Zeldis sells $1.24m in stock - Investing.com
PTC Therapeutics' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com Nigeria
PTC Therapeutics price target raised to $70 from $52 at Baird - MSN
Parkman Healthcare Partners LLC Takes $7.23 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics price target raised to $71 from $47 at UBS - Yahoo Finance
Jacobs Levy Equity Management Inc. Sells 229,494 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Ptc Therapeutics' chief technical officer sells shares worth $3.6 million - Investing.com
PTC Therapeutics' SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone - MSN
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ptc Therapeutics Inc Azioni (PTCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Dec 02 '24 |
Option Exercise |
51.00 |
2,060 |
105,060 |
6,636 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Dec 02 '24 |
Sale |
52.06 |
69,550 |
3,620,895 |
86,202 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Dec 02 '24 |
Sale |
51.97 |
2,060 |
107,063 |
4,576 |
| ZELDIS JEROME B | Director |
Dec 02 '24 |
Option Exercise |
40.93 |
24,000 |
982,320 |
26,500 |
| ZELDIS JEROME B | Director |
Dec 02 '24 |
Sale |
51.50 |
24,000 |
1,235,897 |
14,500 |
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER |
Dec 02 '24 |
Option Exercise |
51.00 |
17,800 |
907,800 |
67,123 |
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER |
Dec 02 '24 |
Sale |
51.77 |
17,800 |
921,585 |
52,428 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Dec 02 '24 |
Option Exercise |
51.00 |
85,600 |
4,365,600 |
176,029 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Dec 03 '24 |
Option Exercise |
33.02 |
10,308 |
340,370 |
100,109 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Dec 02 '24 |
Sale |
52.26 |
85,600 |
4,473,280 |
92,389 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):